Preventing Hair Loss on TRT – 12 Rules to Live by on Testosterone – Doctor’s Guide

Hair loss on testosterone therapy is presented as a predictable issue for many susceptible people. The transcript explains that most shedding follows androgen sensitivity, not simple scalp hygiene mistakes. Male pattern baldness is described as the common pathway when follicles respond strongly to DHT. DHT is discussed as a potent androgen created from testosterone by the 5-alpha reductase enzyme. When TRT raises testosterone levels, more substrate can increase DHT in genetically sensitive scalps. The speaker stresses that prevention is easier than reversal once follicles miniaturize extensively. Readers are encouraged to weigh hair priorities before adjusting doses or adding strong androgens.

The first major prevention tools discussed are 5-alpha reductase inhibitors like finasteride and dutasteride. Finasteride is described as reducing conversion toward DHT, which may slow progressive thinning. Dutasteride is discussed as stronger and broader, yet it can bring more side effects for some men. Sexual side effects and mood changes are mentioned as reasons some users avoid these medications. Topical strategies are also discussed, including ketoconazole shampoo and other scalp-directed treatments. Minoxidil appears as a growth support option that may help density when combined with other measures. Overall, the transcript emphasizes choosing a plan that matches risk tolerance and personal goals.

Several lifestyle and dosing rules are framed as supportive steps for reducing androgenic pressure. Avoiding unnecessary supraphysiologic dosing is described as a straightforward way to reduce DHT load. Keeping additional compounds out of stacks is recommended, because harsher drugs can worsen shedding. Monitoring the prostate is discussed, because DHT also influences enlargement and urinary symptoms. Procedural options like PRP and hair transplantation are mentioned for later-stage loss situations. Even with interventions, the transcript warns that outcomes vary widely based on genetics and timing. The closing message is to make informed tradeoffs and avoid panic-driven protocol changes.